Discovery Life Sciences and Mindpeak Team Up for AI-driven Precision in Cancer Biomarker Testing
New Partnership Enhances Cancer Biomarker Testing with AI
In a groundbreaking initiative, Discovery Life Sciences has partnered with Mindpeak to address persistent inconsistencies in cancer biomarker interpretation. This disparity among pathologists remains a significant obstacle in clinical trials, often leading to variability in patient stratification and diminishing confidence in critical project launch decisions.
This strategic collaboration aims to directly tackle these issues by integrating advanced digital image analysis with AI technologies into immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) services, thereby improving bio-pharmaceutical research capabilities in global clinical studies.
Improving Accuracy and Consistency
The partnership between Discovery and Mindpeak focuses on refining the quantification of biomarkers and enhancing agreement across different reading devices. By minimizing variability linked with biomarker studies, this collaboration intends to bolster trust in essential developmental decisions. Mindpeak brings its AI platform to the table, which acts as a safeguard for bio-pharmaceutical applications, reducing the risks associated with biomarker development through improved interpretation consistency among pathologists.
Additionally, Mindpeak's AI-supported pathology workflows, alongside training sessions provided by the peakAcademy, empower pathologists, ensuring they are better equipped to utilize the latest advancements in digital pathology. The algorithms developed by Mindpeak utilize AI for microdissection tasks, allowing for highly accurate isolation of specific tissue areas—essential for precise biomarker evaluation.
Discovery's Clinical Expertise
On the other hand, Discovery Life Sciences brings extensive clinical infrastructure to the partnership. With its Biomarker Academy, which has educated over 6,000 pathologists since its inception in 2008, Discovery facilitates critical learning in biomarker assessment and interpretation. The company has contributed to more than 2,000 clinical trial programs, with 350 currently active. Over the past four years, it has conducted more than 35 studies across 16 EU countries, ensuring compliance with IVDR regulations involving 25 biomarkers.
This partnership significantly enhances Discovery's pre-existing AI initiatives and builds upon current AI-focused solutions aimed at IHC analysis of biospecimens. Effective measures include automated quality control, tumor quantification, and thorough characterization of the tumor microenvironment across various therapeutic areas.
The Future of Clinical Trials
As stated by Greg Herrema, CEO of Discovery Life Sciences, "Given the increasing adoption of AI in pathology for clinical research, this partnership with Mindpeak allows the integration of modeling tools that can enhance biomarker analysis accuracy. Combining these AI capabilities with our expertise in clinical trials will accelerate the development of biomarker-driven therapies."
The goal of the Mindpeak and Discovery alliance is to streamline trial processes and augment data reproducibility under regulated conditions, ultimately fostering more confident patient stratification and treatment development. Felix Faber, founder and CEO of Mindpeak, expressed, “This collaboration with Discovery Life Sciences provides access to our AI platform, training, and microdissection tools, supporting researchers in IHC and mIF applications, and boosting consistency and confidence in biomarker evaluation.”
More insights regarding the partnership and its applications are expected to be revealed at the upcoming AACR 2026 Annual Meeting. Participants are invited to attend a flash talk at the Discovery Life Sciences booth from April 17-22 at the San Diego Convention Center in California.
About the Companies
Discovery Life Sciences is a global leader in biological samples and specialized laboratory services aimed at drug discovery and diagnostic development, enhancing patient outcomes. Their vast portfolio of quality biospecimens, cellular starting materials, and preclinical ADME-tox solutions supports research with reliable products and expertise. Through specialized services in genomics, proteomics, cellular biology, and molecular pathology, Discovery Life Sciences offers vital data and insights essential for biomarker discovery and clinical trials.
For more insights, visit www.dls.com and follow them on LinkedIn.
Mindpeak is a premier company in digital pathology, utilizing artificial intelligence to bridge the gap between biomarker development and clinical diagnostics. Established in 2018, Mindpeak's AI technology allows laboratories to extract insightful data from HE, IHC, and mIF tissue images—ranging from subcellular biomarker quantification to predictive patient stratification. This technology not only facilitates routine diagnostics but also supports the integration of new biomarkers into real-world clinical practices. For additional details, explore www.mindpeak.ai or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.